Rhythm Biosciences Ltd. (AU:RHY)
ASX:RHY
RHY Stock Chart & Stats
AU$0.14
<AU$0.01(1.16%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(1.16%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.28
Previous CloseN/A
Volume786.78K
Average Volume (3M)462.98K
Market Cap
AU$65.59M
Enterprise ValueAU$63.00M
Total Cash (Recent Filing)AU$1.73M
Total Debt (Recent Filing)AU$262.44K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding345,225,860
10 Day Avg. Volume510,821
30 Day Avg. Volume462,976
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)22.03
Price to Sales (P/S)4.56
P/FCF Ratio-4.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Diagnostic Program (Colostat)Rhythm's clear product focus on Colostat, a blood-based colorectal screening test for population screening and clinical pathways, gives a durable commercialization target. Successful integration into screening programs and clinical pathways can produce recurring volumes and stable long-term revenue streams if adoption progresses.
High Gross MarginsReported high gross margin indicates favorable unit economics at the product level. Over the medium term, strong gross margins provide structural leverage to cover fixed costs and support moves to positive EBITDA as sales scale, improving resilience to margin compression from pricing or input cost changes.
Improving Free Cash Flow TrendImproving free cash flow growth and an FCF-to-net-income ratio slightly above 1 signal better cash conversion. Sustained FCF improvement reduces dependence on external funding, extends runway for commercialization and R&D, and is a durable operational improvement versus short-term profit swings.
Bears Say
Sharp Recent Revenue DeclineA 42.87% year decline in revenue is a structural concern: it reduces scale, undermines fixed-cost absorption, and slows path to profitability. Persistent top-line contraction raises questions about market adoption, reimbursement progress, and the commercial effectiveness required to sustain long-term operations.
Persistent Unprofitability And Negative MarginsOngoing negative net, EBIT and EBITDA margins indicate the business currently cannot cover operating costs from revenue. This structural profitability gap limits reinvestment, heightens financing needs, and means the company must either materially grow revenue or materially cut costs to reach self-sustaining operations.
Elevated Leverage And Negative Operating Cash FlowA debt-to-equity ratio of 1.68 combined with negative operating cash flow creates medium-term liquidity and refinancing risk. Elevated leverage constrains strategic flexibility and increases the need for external capital, which can dilute shareholders or limit the firm's ability to fund commercialization and clinical development.
Rhythm Biosciences Ltd. News
RHY FAQ
What was Rhythm Biosciences Ltd.’s price range in the past 12 months?
Rhythm Biosciences Ltd. lowest share price was AU$0.05 and its highest was AU$0.28 in the past 12 months.
What is Rhythm Biosciences Ltd.’s market cap?
Rhythm Biosciences Ltd.’s market cap is AU$65.59M.
When is Rhythm Biosciences Ltd.’s upcoming earnings report date?
Rhythm Biosciences Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 142 days.
How were Rhythm Biosciences Ltd.’s earnings last quarter?
Rhythm Biosciences Ltd. released its earnings results on Feb 18, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.
Is Rhythm Biosciences Ltd. overvalued?
According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued.
Does Rhythm Biosciences Ltd. pay dividends?
Rhythm Biosciences Ltd. does not currently pay dividends.
What is Rhythm Biosciences Ltd.’s EPS estimate?
Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rhythm Biosciences Ltd. have?
Rhythm Biosciences Ltd. has 345,225,860 shares outstanding.
What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?
Rhythm Biosciences Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.381%.
Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?
Currently, no hedge funds are holding shares in AU:RHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Biosciences Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RHY Sentiment 66%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$34.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.00%
12-Months-Change
Fundamentals
Return on Equity
-476.27%
Trailing 12-Months
Asset Growth
-47.76%
Trailing 12-Months
Company Description
Rhythm Biosciences Ltd.
Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―